Oncofertility — the specialized field combining oncology and reproductive medicine to preserve fertility in cancer patients before gonadotoxic treatments — represents a specialized but growing fertility market segment driven by improving cancer survival rates, with the Fertility Services Market reflecting oncofertility as an important fertility subspecialty market.

ASCO oncofertility guideline recommendations — the American Society of Clinical Oncology guidelines recommending fertility preservation counseling and referral for all reproductive-age patients prior to gonadotoxic chemotherapy or radiation — create the standard of care framework that drives oncofertility clinic referrals. The estimated one hundred thousand reproductive-age cancer patients annually in the US represent the target population for oncofertility counseling with a significant proportion pursuing preservation attempts.

Ovarian tissue cryopreservation advances — the experimental-to-established-practice evolution of ovarian cortex tissue cryopreservation and reimplantation for fertility restoration after cancer treatment — represents the oncofertility innovation that enables fertility preservation even when ovarian stimulation for egg freezing is not feasible from hormone-sensitive cancers or urgent treatment timelines. The first live births from orthotopic ovarian tissue reimplantation established clinical proof-of-concept for this preservation approach in the late 2000s.

Oncofertility fertility network development — the national networks connecting oncologists with reproductive specialists (LIVESTRONG Fertility, Fertile Hope, and institutional oncofertility programs) — have improved cancer patient access to timely fertility consultation that treatment urgency often constrains to days rather than weeks. Same-day or next-day fertility consultation protocols at major cancer centers create the clinical workflow that enables fertility preservation without unacceptable cancer treatment delay.

Do you think oncofertility services are adequately integrated into cancer care workflows, or do significant patient access gaps from inadequate oncologist-to-reproductive-specialist referral pathways remain?

FAQ

What fertility preservation options are available for cancer patients? Female cancer patients' fertility preservation options include: oocyte cryopreservation (egg freezing — standard option requiring ten to fourteen days stimulation), embryo cryopreservation (requires partner/donor sperm, most established option with best success data), ovarian tissue cryopreservation (rapidly removed surgically, reimplanted post-treatment — accepted standard since 2019), and GnRH agonist ovarian suppression during chemotherapy (may reduce gonadotoxic injury, evidence mixed); male cancer patients can bank sperm through ejaculation or TESE before treatment; treatment urgency, cancer type (hormone-sensitive limitations), and patient age affect option selection.

What is LIVESTRONG Fertility? LIVESTRONG Fertility is a program providing free or reduced-cost fertility preservation services for cancer patients who cannot afford treatment; provides discounted (sometimes free) medications through pharmaceutical partnerships, reduced-fee connections with partner fertility clinics, and financial assistance information; serves uninsured and underinsured cancer patients nationally; patients apply online with cancer diagnosis documentation; program has assisted over fifty thousand cancer patients since 2004; partnerships include major fertility medication manufacturers providing donated medications; program enables oncofertility access for patients facing both cancer treatment costs and fertility preservation costs simultaneously.

#FertilityServices #Oncofertility #CancerFertility #EggFreezingCancer #OncofertilityMarket #FertilityPreservationCancer